- Open Access
Correction to: P-42 Distribution and antifungal susceptibility of Candida isolates in a Tunisian burn unit
Annals of Intensive Care volume 9, Article number: 80 (2019)
Correction to: Ann. Intensive Care 2018, 8(Suppl 1):13 https://doi.org/10.1186/s13613-017-0345-7
After publication of this supplement , it was brought to our attention that in abstract P-42 an author’s name has been erroneously spelled. It should be read “Hanachi Majdi” instead of “Hanchi Majdi”.
Introduction: Burned patients are at high risk of yeast colonization and thus of invasive fungal infections, particularly to Candida (C.) spp., leading to an increase in morbidity and mortality. While pre-emptive antifungal therapy has improved survival, it may lead to an increase in antifungal resistance. The objectives of this work were to describe Candida species distribution and to determine the antifungal susceptibility of Candida isolates acquired in a burn unit.
Patients and methods: Our study is a retrospective review of 17 severely burned patients admitted to the burn unit of the Ben Arous Traumatology and Burns Center with one or more positive culture sites for Candida, during the 16-month period from May 2016 through August 2017. A total of 42 isolates were thus obtained. The susceptibility to 6 antifungal drugs (5-fluorocytosine, fluconazole, ketoconazole, miconazole, itraconazole and amphotericin B) was determined using the Fungitest® broth dilution method for patients with infected normally sterile body sites or a Candida colonization index superior or equal to 0.4. Since echinocandin and anidulafungine were recently introduced in Tunisia, the susceptibility to these antifungal classes was tested for only one patient from our cohort.
Results: Nasal and buccal sites were the most colonized body sites (21.4% each), followed by axillary (11.9%) and rectal sites (9.5%) and urines (9.5%). C. albicans was the predominant species (45.2%), followed by C. glabrata (38.1%), C. tropicalis (7.1%) and C. parapsilosis (4.8%). Among the strains whose antifungal susceptibility was determined, majority of Candida isolates were susceptible to fluconazole (77.8%), which is the most frequently used molecule as a pre-emptive treatment in such cases in Tunisia due to its availability and its efficiency. On the other hand, 11.1% of the isolates were intermediate and 11.1% were resistant to this antifungal drug, mainly C. glabrata for both groups. As for the other tested azoles, high rates of intermediate strains were noticed (81.5% to itraconazole, 40.7% to ketoconazole and 33.3% to miconazole), mostly C. glabrata. Only one strain was resistant to amphotericin B, which is not usually used in these cases due to its nephrotoxicity and the frequency of kidney failure in burned patients.
Conclusion: Our study demonstrates that C. albicans is the most frequent species in burn unit-acquired candidiasis. No major antifungal resistance was observed, apart from high rates of intermediate strains (mainly C. glabrata) to azole class antifungal drugs.
Sonia T, Majdi H, Meriam B, Dorsaf A, Sarra C, Samira K, Allah MA, Lamia T. Proceedings of Réanimation 2018, the French Intensive Care Society International Congress. Ann Intensive Care. 2018;8(Suppl 1):P-42. https://doi.org/10.1186/s13613-017-0345-7.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Sonia, T., Majdi, H., Meriam, B. et al. Correction to: P-42 Distribution and antifungal susceptibility of Candida isolates in a Tunisian burn unit. Ann. Intensive Care 9, 80 (2019). https://doi.org/10.1186/s13613-019-0555-2